Penn Medicine is conducting medical studies to develop new diagnostic and clinical treatments to improve current standards of care.
Recently Added/Updated trials
tACS Language
The research study is being conducted to test if a form of noninvasive brain stimulation,called transcranial alternating current stimulation (tACS), will improve a person’s abilityto name objects more than fake tACS. TACS is a technique by which small electriccurrents are applied to the scalp. This creates coordinated brain activity across thebrain. This study also involves electroencephalography (EEG). EEG is a method ofrecording brain activity through electrodes placed on the scalp.CURRENTLY, WE ARE RECRUITING HEALTHY PARTICIPANTS BETWEEN THE AGES OF 45 AND 85 YEARS OLD.We will begin to recruit participants with aphasia in the spring of 2025.
IMAGING OF PRIMARY OR RECURRENT GYNECOLOGICAL CANCER WITH [18F]FLUORTHANATRACE ([18F]FTT) PET/CT
The purpose of this study is to study a new radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body to see how it is taken up in the body and the brain using an imaging procedure called Positron Emission Tomography (PET/CT). Imaging PARP-1 activity in various cancers may help researchers to better understand it’s function and determine the best way to use imaging to help study new treatments that target the PARP-1 enzyme.
RevitaT2Di Pivotal Study (REVITALIZE 1)
The Revitalize-1 Study will look at a potential procedure called duodenal mucosal resurfacing (DMR). The DMR procedure acts on the first layer (mucosa) of the duodenum (the part of the small intestine located immediately after the stomach). By removing an excess layer, the treatment may improve blood sugar control. This treatment may eliminate or reduce the need for insulin injections in the future for the treatment of Type 2 Diabetes.
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation
(HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for
peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in
children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil
(MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will
study how well this treatment works in patients with hematologic malignancies.
A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral ATRN-119 in Patients with Advanced Solid Tumors
The study will evaluate the safety profile of escalating doses of continuous daily oral ATRN-119 and to determine the maximum tolerated dose (MTD) and recommended dose.
ATRN-119 is a drug that has been developed to treat cancers by taking advantage of genetic mutations found only in the tumor and not in normal tissue.
CureTalks@Penn interviews Penn Medicine physicians about their cutting edge research and clinical trials. Our goal is to inform patients, care-givers, patient advocates and other physicians about research that occurs at Penn Medicine.
